ALVAL Valbiotis SA
Valbiotis SA engages in the research and development of dietary supplements to prevent metabolic and cardiovascular diseases in France and Asia. The company offers supplements for immunity and vitality, health and wellbeing, metabolic and cardiovascular health, and beauty and physical comfort. It also develops TOTUM-63 for the reduction of fasting blood glucose and treatment of type 2 diabetes; TOTUM-854, which is in Phase II/III clinical trials for reducing systolic blood pressure; and TOTUM-448 for the reduction of hepatic steatosis. Additionally, the company offers e-commerce delivery service in Belgium and Luxembourg. Valbiotis SA was incorporated in 2014 and is based in Périgny, France.…
Industry Peers
Packaged FoodsKey Statistics
About Valbiotis (EPA: ALVAL)
›
Valbiotis (EPA: ALVAL) is listed on Euronext Paris, where its shares trade in EUR. It belongs to the Packaged Foods industry, part of the Consumer Defensive sector, and reports about 50 employees.
The shares were at 0.5800 EUR on 19 November 2026, down 29.3% over 52 weeks. Its 52-week range is 0.4860 EUR to 1.296 EUR: the price is 55.2% below the high and 19.3% above the low.
Its market capitalisation is 20.58M EUR.
Valbiotis reports return on equity of -135.3% and revenue up 129.7% year over year.
It holds more cash than debt, a net cash position of 7.43M EUR. Its Piotroski F-score is 3 out of 9, a weak reading of its financial health. 2 analysts cover the stock; their mean price target of 1.350 EUR is 132.8% above the current price.